Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;148(1):163-176.
doi: 10.1007/s00432-021-03840-y. Epub 2021 Oct 26.

Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns

Rilan Bai  1 , Xiao Chen  1 , Wei Song  1 , Huimin Tian  1 , Jiuwei Cui  2
Affiliations

Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns

Rilan Bai et al. J Cancer Res Clin Oncol. 2022 Jan.

Abstract

Background: EGFR exon 20 insertion (EGFR ex20ins) mutations account for about 10-12% of all EGFR-mutated tumors, which are usually associated with primary drug resistance to conventional EGFR-TKI therapy and worse survival outcomes, and are currently a major problem for clinicians in clinical management. In recent years, with the rapid improvement of sequencing technology and careful review of clinical data, investigators have gained a deeper understanding and clearer cognition of the clinicopathological features and molecular mechanisms of these EGFR ex20ins mutations.

Purpose: The aim of this study was to systemically review the molecular structure and clinical characteristics of EGFR ex20ins mutations, and focus on summarizing the latest data of emerging therapies (including novel small-molecule EGFR-TKI drugs, specific monoclonal antibodies, novel drugs targeting other mechanisms, and immunotherapy) for those patients.

Conclusion: Advances in overcoming these systemic challenges have greatly accelerated the development of new drugs targeting EGFR ex20ins, and are committed to designing more rational combination therapies to overcome or delay the emergence of drug resistance, ultimately improve the prognosis of such uncommon mutant populations.

Keywords: Bispecific antibody; EGFR exon 20 insertion; Immune checkpoint inhibitor; Lung cancer; Tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest are disclosed.

References

    1. Arcila ME, Nafa K, Chaft JE et al (2013) EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 12(2):220–229. 10.1158/1535-7163.Mct-12-0620 (PMID:23371856) - DOI - PMC - PubMed
    1. Beau-Faller M, Prim N, Ruppert AM et al (2014) Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 25(1):126–131. 10.1093/annonc/mdt418 (PMID:24285021) - DOI - PMC - PubMed
    1. Cardona AF, Rojas L, Zatarain-Barrón ZL et al (2018) EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP). Lung Cancer 125:265–272. 10.1016/j.lungcan.2018.10.007 (PMID:30429031) - DOI - PubMed
    1. Cha MY, Lee KO, Kim M et al (2012) Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer 130(10):2445–2454. 10.1002/ijc.26276 (PMID:21732342) - DOI - PubMed
    1. Chen K, Cheng G, Zhang F et al (2020) PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. Lung Cancer 142:98–105 - DOI - PubMed

Publication types

MeSH terms